Sanofi signs personalised medicine alliance
pharmafile | August 11, 2010 | News story | Research and Development |Â Â Sanofi-Aventis, Scripps Genomic Medicine, genomicsÂ
Sanofi-Aventis has signed a personalised medicine research alliance with US not-for-profit company Scripps Genomic Medicine.
The company is part of the California health care delivery network Scripps Health, whose patients it works with to collect genetic data that can help better define the role genes play in human health, disease and medical conditions.
Sanofi’s executive VP of research & development Marc Cluzel said: “Our alliance with Scripps underscores Sanofi-Aventis’s commitment to collaborating with a range of innovative partners focused on cutting-edge scientific research and development initiatives.
“Personalised medicine, particularly the application of genomics, has the potential to vastly improve patient health. This partnership seeks to significantly enhance our research activities in this important field.”
Under the terms of their alliance, Sanofi’s Recherche & Developpement subsidiary will fund up to three discovery innovation grants per year Scripps Genomic Medicine’ projects.
In turn, Sanofi will be granted non-exclusive rights to any research tools developed, and have preferred access to Scripps’s laboratory facilities for work in support of the sponsored research agreements.
In addition, through ongoing scientific exchange and collaboration, Sanofi will have access to Scripps research programmes that contribute to the company’s key therapeutic areas.
Dr Eric Topol, chief academic officer of Scripps Health, said the alliance was an example of the ideal collaboration between pharma and the non-profit research community.
“The partnership aims to foster an environment of open scientific exchange in genomic medicine that we hope will translate to new discoveries to benefit patients while establishing a collaborative approach to drug development.”
Ben Adams
Related Content
Broken String Biosciences and the Francis Crick Institute collaborate on ALS research
Genomics company Broken String Biosciences and biomedical discovery institute Francis Crick have announced a research …
AstraZeneca’s Alexion partners with Pfizer for rare disease therapies
Alexion, AstraZeneca’s Rare Disease division, has announced that it has entered a definitive purchase and …
Manchester emerges as genomics research hub
Manchester, UK is emerging as a major hub for genomics research, according to a new …
